NeOnc Technologies (Nasdaq: NTHI) Announces AI-Driven Findings Showing Ultrasound Enhances the Potency of an Already Effective NEO100 in Treating Primary and Metastatic Brain Tumors

NeOnc Technologies revealed preclinical research demonstrating that ultrasound can enhance the therapeutic potency of NEO100 for treating primary and metastatic brain tumors, using an AI-driven 3D-bioprinted methodology.

12/01/2025, 9:00 AM • GlobeNewswire

NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Data Updates from Ongoing NEO100-1 Phase 1/2a Clinical Trial and Compassionate Use Program

NeOnc Technologies will host an investor conference call to present data updates from its ongoing Phase 1/2a NEO100-1 clinical trial, focusing on intranasal delivery of NEO100 for treating recurrent high-grade malignant glioma.

11/07/2025, 9:00 AM • GlobeNewswire

NeOnc Technologies' Subsidiary, NuroMENA, Signs Master Services Agreement with M42’s IROS and Expands Board of Directors

NeOnc Technologies' subsidiary NuroMENA signed a Master Services Agreement with IROS, part of M42, to accelerate clinical cancer therapy development in the Middle East. The company also expanded its NuroMENA board by adding members from Quazar Investment.

10/09/2025, 9:00 AM • GlobeNewswire

NeOnc Technologies Appoints Renowned Neuro-Oncologist Dr. Henry S. Friedman to Scientific Advisory Board

NeOnc Technologies has appointed renowned neuro-oncologist Dr. Henry S. Friedman to its scientific advisory board, strengthening its expertise in developing therapies for central nervous system cancers.

09/29/2025, 9:00 AM • GlobeNewswire

NeOnc Technologies Closes Strategic Acquisition of Advanced AI and 3D Bioprinting IP, Appointing World-Renowned Scientist Dr. Ishwar K. Puri to its Board

NeOnc Technologies acquired an intellectual property portfolio featuring AI, 3D bioprinting, and quantum modeling technologies for $3.5 million, enhancing its drug discovery capabilities for central nervous system cancer therapies. Dr. Ishwar K. Puri was appointed to the company's Board of Directors.

08/25/2025, 9:00 AM • GlobeNewswire

NeOnc Technologies Awarded $2.5 Million in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia

NeOnc Technologies received two NIH STTR grants totaling $2.5 million to advance NEO212, a therapeutic compound targeting central nervous system malignancies, with ongoing Phase 1 clinical trials and potential applications in acute myelogenous leukemia and gliomas.

08/07/2025, 9:00 AM • GlobeNewswire

NeOnc Technologies Signs Definitive Agreement to Acquire AI, 3D, and Quantum Modeling IP Portfolio from Dr. Ishwar K. Puri; Appoints Him to Board of Directors

NeOnc Technologies has signed a $3.5 million agreement to acquire an IP portfolio focused on AI, 3D bioprinting, and quantum modeling technologies from Dr. Ishwar K. Puri, who will also join the company's Board of Directors.

07/30/2025, 9:00 AM • GlobeNewswire

CORRECTING and REPLACING - NeOnc Technologies Holdings, Inc.

NeOnc Technologies, a clinical-stage biotechnology company, announced its Executive Chairman will participate in a live interview on YouTube, following a recent sub-license agreement with NuroCure and inclusion in the Russell Microcap Index.

07/23/2025, 10:53 AM • GlobeNewswire

NeOnc Technologies Signs $50 Million Non-Binding Strategic Term Sheet with Quazar Investment to Launch GCC & MENA Expansion and Clinical Trials Platform

NeOnc Technologies has signed a non-binding $50 million term sheet with Quazar Investment to establish NuroMENA Holdings and NuroCure, a new UAE-based platform for clinical trials in brain cancer treatments across the MENA region.

07/08/2025, 9:00 AM • GlobeNewswire